History of New Horizons Collaborative
In response to the urgent need for life-saving HIV medication in sub-Saharan Africa—especially among children and adolescents—Johnson & Johnson and its partners launched New Horizons in 2014, initially covering Eswatini, Kenya, South Africa, and Zambia. Over the next four years, New Horizons would expand to serve seven additional countries—Lesotho, Uganda, Cameroon, Nigeria, Rwanda, Zimbabwe and Republic of Congo. Through collaboration and careful planning, New Horizons has successfully supported children living with HIV, increased access to second- and third-line HIV treatment for pediatric patients and offered capacity building services to providers and clinicians.
Building on six years of progress, in July 2021, Johnson & Johnson, the Elizabeth Glaser Pediatric AIDS Foundation and its other partners renewed commitments to the New Horizons Collaborative and announced enhancements to the program to help maximize its reach and impact for children and adolescents living with drug-resistant forms of HIV across sub-Saharan Africa. Under the next phase of the program, New Horizons will continue enrolling new HIV patients through at least 2025. Johnson & Johnson, through its Janssen Pharmaceutical Companies, will continue donating important second- and third-line medicines to treat pediatric and adolescent patients previously enrolled in the program and those who will be enrolled in the future until they turn 24 years of age, at which point they will be transitioned into national adult HIV treatment programs. In addition, New Horizons will continue strengthening the capacity of health systems in the 11 participating countries to advance pediatric and adolescent HIV care and enhance core program elements, including access to medicines, supply-chain strengthening and data generation.